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Zusammenfassung
Hintergrund und Gegenstand: Im Rahmen der etablier-
ten Tumorbehandlungen hat die Strahlentherapie ihren
festen Stellenwert. Auch die Anwendung der photodyna-
mischen Therapie (PDT), insbesondere mit Photofrin II,
ist in der Tumorbehandlung bekannt. Chemische Stoffe,
die die Wirkung von ionisierenden Strahlen am Tumor-
gewebe verstärken können, werden bereits in der Medi-
zin genutzt. Keiner dieser Stoffe ist aber ein selektiver
Radiosensitizer. Material und Methoden: Mehrere Serien
von Tierexperimenten wurden durchgeführt. Nackt-
mäusen wurden subkutan hochdifferenzierte humane
Blasenkarzinom-Zelllinien RT4 implantiert. Den Mäusen
wurde 10 mg/kg Photofrin II injiziert, danach wurden sie
mit 5 Gy bestrahlt. Ergebnisse: Photofrin II hat sich als
chemischer Modulator der biologischen Wirkung ionisie-
render Strahlen erwiesen. Dies wurde mit der Erhöhung
der Tumorverdopplungszeit (Tumorwachstumskurve)
von 6,2 auf 10,9 Tage in der Kontrollgruppe bei Anwen-
dung ionisierender Strahlen und Injektion von Porphyrin
bewiesen. Schlussfolgerung: Photofrin II zeigt eine gute
Wirksamkeit als Radiosensitizer und kann in Zukunft als
selektiver Radiosensitizer bei der Tumorbehandlung mit
ionisierenden Strahlen genutzt werden. 
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Summary
Background and Objective: The use of ionizing irradia-
tion as radiation therapy (RT) for tumor treatment repre-
sents a well-established method. The use of photody-
namic therapy (PDT), especially with Photofrin II, for
tumor treatment is also known. Chemical modifiers en-
hancing the action of radiation therapy are well known
and widely used in medicine. None of these compounds,
however, is a selective radiosensitizer. Materials and
Methods: Several series of animal experiments were per-
formed. The highly differentiated human bladder cancer
cell line RT4 was implanted subcutaneously in nude
mice. The mice were injected 10 mg/kg Photofrin II and
irradiated with 5 Gy. Results: Photofrin II has proved to
be a chemical modifier of ionizing irradiation, enhancing
the tumor doubling time (tumor growth) from 6.2 to 10.9
days in the control group with the use of irradiation and
injection of porphyrin. Conclusion: Photofrin II shows a
high activity as radiosensitizer and, in the future, can be
used as a selective radiosensitizer for tumor treatment
with ionizing radiation. 
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Introduction
Recently, Photofrin II has been approved as a photosensitiz-
ing agent for the clinical treatment of selected solid tumors by
what is called photodynamic therapy (PDT) [1]. In spite of
the objectively positive response observed in a few thousand
patients treated worldwide by PDT with Photofrin [2], some
important limitations are associated with this phototherapeu-
tic modality. Thus, Photofrin II has a small molar extinction
coefficient in the clinically useful red spectral region, which
limits the efficiency of its activation by light. Moreover, the
630-nm wavelength, which corresponds to the red absorption
maximum of Photofrin II, is endowed with reduced penetra-
tion power within most human tissues [3]. Such limitation
could explain both the need for repetition of PDT sessions
with Photofrin II and the frequent recurrences observed for
tumors even after an apparently extensive photo-induced
damage [4].
Therefore, several investigations are focused on the potentia-
tion of the phototherapeutic action of Photofrin II by combin-
ing PDT with different therapeutic approaches such as radio-
therapy, chemotherapy or surgery [1].
The biochemical effects, dependent on cellular physiology
(oxygen, cell cycle), may be modifiable by adding chemicals
(sensitizers, protectors, chemotherapy) [5]. This modification
is important in order to achieve a maximum effect on the tu-
mor with minimum effect on the normal tissue. These compo-
nents are radiosensitizers which, when combined with radia-
tion, will achieve a greater tumor inactivation than one ex-
pects from the additive effect of each modality.
In the 1960s, Choen and Schwartz [6] first showed that a
hematoporphyrin derivative (HpD, a photosensitizing por-
phyrin) can also be used as a radiosensitizer for tumor treat-
ment by ionizing radiation. This observation was confirmed
by a later report [7]. Now, Photofrin II is a purified version of
HpD [8]. It is therefore of interest to explore its radiosensitiz-
ing efficacy in order to promote a synergistic action between
photo- and radiotherapy by using just one approved sensitiz-
ing agent. 
Material and Methods
Photofrin was received from QLT (Vancouver, Canada) and stored as a
stock solution with a porphyrin concentration of 10 mg/ml as assessed by
absorption spectroscopic measurements. This formulation appeared to be
stable for several weeks provided it was kept in dim light and at a temper-
ature of below 15 °C .
The animals used in our experiments were nude mice (Charles River, Co-
mo, Italy) bearing a subcutaneously transplanted bladder carcinoma
(RT4 cells) [9]. The mice were of female gender, with a body weight of
20–22 g. They were incubated in the dorsal region with 2x106 cells/ml of a
sterile physiological solution. On the 7th day posttransplantation, when
the tumor volume (as measured with calliper) was 2.6–3.0 mm3, a group
of 10 mice was injected into the tail vein with a Photofrin dose of 10
mg/kg body weight. 24 h after administration of the porphyrins, the mice
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were sacrificed by overexposure to ether vapors. The tumor, normal skin,
liver and serum were quickly removed, homogenized, and the porphyrin
was extracted by a 1-hour incubation of 2% aqueous sodium dodecyl sul-
fate (SDS). The porphyrin concentrations in such tissue extracts were de-
termined by a spectrophotofluorometer procedure [10].
Two other groups of nude mice (10 per group) which had received 10
mg/kg Photofrin were exposed to ionizing irradiation (Siemens X-Rays
device 50 kVP, 25 mA) with a total dose of 5 and 15 Gy, respectively, 24 h
after the injection of porphyrin. The tumor growth rate, as determined by
the tumor volume, was measured at daily intervals. The radiosensitized
mice were compared with 3 control-observed groups of 10 mice each: un-
treated, Photofrin-treated (no irradiation), and 15-Gy-treated (no por-
phyrin) mice. In all cases, during irradiation the mice were kept under
light anesthesia by intraperitoneal injection of Ketolon. To avoid activa-
tion of the porphyrin by light, the mice were held in a special, dark room.
Results
As can be seen from table 1, intravenously injected Photofrin
is accumulated in significant amounts by our tumor model 24
h postinjection. Appreciable amounts of Photofrin are also
recovered from the skin and the serum, which agrees with the
observations of previous authors [11]. On the other hand,
largest recoveries of Photofrin were obtained from the liver,
as one should expect, since this relatively hydrophobic por-
phyrin is predominantly excreted from the bile-gut pathway
[12].
Based on the pharmacokinetic results, the tumor-bearing mice
were exposed to ionizing irradiation 24 h postinjection. Clear-
Table 1. Recovery of intravenously injected (10 mg/kg) Photofrin from
irradiated and control mice 
Tissue Recoverya

µg/g µg/ml
Tumor 0.58 ± 0.17
Liver 2.79 ± 0.40
Skin 0.35 ± 0.11
Serum 0.55 ± 0.07
aThe recovery was estimated 24 h postinjection. Values are mean ± SD.
Table 2. Tumor growth delay (∆t) for control and Photofrin-radiosen-
sitized nude mice bearing a subcutaneously implanted RT4 bladder
carcinoma
Groupa ∆t, days
Control 5.9
Photofrin (10 mg/kg) only 6.4
5 Gy only 6.4
15 Gy only 8.4
Photofrin (10 mg/kg) + 5 Gy 10.9
aEach group comprised 10 mice.
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ly, as shown in figure 1, the Photofrin II-loaded tumor showed
a markedly slower growth rate compared with the control
groups. The delay of the tumor growth was calculated for the
various groups and is summarized in table 2. Such a delay is
expressed as the time necessary for the tumor to double its
original volume. In general, the bladder carcinoma would
grow at an aggressive rate, leading to the death of the tumor-
bearing mice within 17 days from implantation.
Discussion
The present findings unequivocally demonstrate that
Photofrin II can act as a radiosensitizing agent for tumors.
The subcutaneously implanted bladder carcinoma showed a
clearly detectable response in all the Photofrin II-injected and
-irradiated mice, where the injection of Photofrin II per se
and the irradiation alone had no appreciable effect. In fact,
the tumor growth rate in all the control animals was almost
the same. This is especially evident because RT4 human blad-
der cancer, the tumor model used, is known as aggressive and
radiation-resistent [13]. This can also be seen in our results:
the effect of 5 Gy irradiation on the tumor showed no change;
the effect of 15 Gy caused a tumor growth delay of 8.4 days,
and combined treatment of both 5 Gy and Photofrin II
showed a delay of 10.9 days. The effect of 5 Gy with Photofrin
II on the tumor is higher in long-term observation than that of
15 Gy alone. 
It therefore appears reasonable to conclude that Photofrin II
behaves in a similar way as the less purified analogue HpD.
The radiosensitizing effect of this porphyrin appears to be op-
timal already at relatively small radiation doses; no increase
of the radiation effects, observed in the presence of Photofrin,
was induced by an increase of the total radiation dose from 5
to 15 Gy. In general, PDT with Photofrin II causes the delay
in tumor growth induced by the combined action of Photofrin
II and ionizing irradiation in the same animal model [14].
Consequently, we can assume that a synergistic action takes
place between the two therapeutic modalities.
Of course, the achievement of this goal is dependent on the
definition of the factors controlling the efficiency and on the
mechanism of the radiosensitizing action of Photofrin. In the
first place, it is well known that Photofrin II, even though it
represents a purified version of HpD, is a complex mixture of
monomer, dimer and oligomer hematoporphyrin derivatives;
hence, it is certainly important to investigate whether some
specific components of Photofrin II provide a major contribu-
tion to the overall effects of the irradiation procedure. Toward
this aim, we are presently undertaking a thorough study on
the relationship between the chemical structure and the ra-
diosensitizing activity of various porphyrins and their ana-
logues (e.g. phtalocyanines).
At the same time, parallel investigations will be carried out to
assess the role performed by selected experimental parame-
ters in modulating the response of tumors to Photofrin ra-
diosensitization, inclusive of the total irradiation dose, the
time interval between porphyrin injection and irradiation as
well as the administered porphyrin dose. Particular attention
will be given to the identification of the lowest Photofrin con-
centration which promotes an efficient response of the neo-
plastic lesion.
A minimization of the systemically injected porphyrin dose
would, in fact, significantly reduce the risk of persistent skin
photosensitivity, which constitutes one important side effect
of Photofrin-PDT [14]. 
The results of such investigations could either support the fea-
sibility of a combined radio-/phototherapy with Photofrin II
or even identify some applications where radiotherapy with
Photofrin II becomes clinically relevant [15,16]. 
Fig. 1. The Photofrin II-loaded tumor showed a markedly slower growth
rate compared with the control groups.
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